Stockwinners Market Radar for May 28, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:08 EDT T-Mobile to acquire U.S. cellular operations of UScellular for $4.4B - T-Mobile (TMUS) and UScellular (USM) "announced that T-Mobile has agreed to acquire substantially all of UScellular's wireless operations. This includes UScellular's wireless customers and stores, as well as certain specified spectrum assets. Upon closing, T-Mobile's leading 5G network will expand to provide millions of UScellular customers, particularly those in underserved rural areas, a superior connectivity experience, moving from a roaming experience outside of the UScellular coverage area to full nationwide access on the country's largest and fastest 5G network. Additionally, UScellular customers will have the ability to fully participate in the Un-carrier's industry-leading value-packed plans filled with benefits and perks, and best-in-class customer support with the opportunity to save UScellular customers hundreds of millions of dollars. T-Mobile customers will also get access to UScellular's network in areas that previously had limited coverage and the benefit of enhanced performance throughout UScellular's footprint from the addition of the acquired UScellular spectrum to T-Mobile's network. And wireless consumers across the country will benefit from the enhanced choice and competition that this proposed transaction will create. T-Mobile will pay approximately $4.4 billion for the assets being acquired from UScellular in the transaction in a combination of cash and up to $2.0 billion of debt to be assumed by T-Mobile through an exchange offer to be made to certain UScellular debtholders prior to closing. To the extent any debtholders do not participate in the exchange, their bonds will continue as obligations of UScellular and the cash portion of the purchase price will be correspondingly increased. Following the closing of the transaction, UScellular will retain ownership of its other spectrum as well as its towers, with T-Mobile entering into a long-term arrangement to lease space on at least 2,100 additional towers being retained. T-Mobile does not expect the transaction to impact the company's 2024 guidance or 2024 authorized shareholder return program. T-Mobile expects this transaction will yield approximately $1.0 billion in effective total opex and capex annual run rate cost synergies upon integration, with total cost to achieve the integration currently estimated at between $2.2 billion to $2.6 billion. The company plans to reinvest a portion of synergies toward enhancing consumer choice, quality and competition in the wireless industry. The transaction, which is subject to the satisfaction of customary closing conditions and receipt of certain regulatory approvals, is expected to close in mid-2025."

20:08 EDT Cathie Wood's ARK Investment bought 135K shares of Roblox today

19:50 EDT Visionary Holdings Inc trading halted, news pending

19:30 EDT Cathay General adopts new $125M share buyback program - Cathay General announced that its Board of Directors has adopted a new share repurchase program authorizing the Company to repurchase up to $125,000,000 of the Company's common stock. The previous $125,000,000 share repurchase program announced on May 26, 2022, was completed on February 21, 2023, with the repurchase of 2,897,628 shares at an average cost of $43.14.

18:34 EDT Snowflake CAO sells 6,500 class A shares - In a regulatory filing, Snowflake chief accounting officer Emily Ho disclosed the sale of 6,500 class A common shares of the company on May 24 at a price of $158.36 per hsare.

17:58 EDT OmniAb CEO buys $1.06M in common stock - In a regulatory filing, OmniAb disclosed that its CEO Matthew Foehr bought 240K shares of common stock on May 24th in a total transaction size of $1.06M. Shares of OmniAb are up 3% afterhours at $4.30.

17:45 EDT KKR to buy Emera's equity interest in Labrador Island Link for CAD$1.19B - Emera and KKR announced they have entered into a definitive agreement where KKR will acquire Emera's indirect minority equity interest in the Labrador Island Link LIL . The transaction value is $1.19B CAD, made up of $957M CAD in cash and $235 million CAD for assuming Emera's obligation to fund the remaining initial capital investment. "We're pleased to be part of the future success of the Labrador Island Link." As part of its overall commitment to the Lower Churchill Project, Emera has been an equity investor in the construction of the LIL alongside Newfoundland and Labrador Hydro which owns and operates the LIL. The transaction announced provides for a one-time, up-front payment at closing in exchange for Emera's indirect interest in the LIL, meaning KKR will receive quarterly distribution payments over the remaining life of the 50-year LIL contract and allow Emera to reduce corporate debt and fund its investments in its regulated utility businesses. Emera will remain actively engaged in the LIL partnership, along with NL Hydro, by continuing to provide sustaining capital investments to support ongoing operations. This transaction has no impact on Emera's ownership of the Maritime Link transmission line and no impact on Nova Scotia Power, or its customers... The transaction is expected to close on or about June 4.

17:32 EDT Four Corners buys National Veterinary Associates property for $1.8M - Four Corners Property Trust announces the acquisition of a National Veterinary Associates property for $1.8M. The property is located in Florida and is corporate-operated under a new long-term, triple net lease with annual rent bumps. The transaction was priced at a cap rate in range with previous FCPT transactions.

17:13 EDT TJX CEO Herrman sells over $2M in company shares - The CEO of TJX Companies Ernie Herrman disclosed the sale of 20,000 shares of company stock at $102.17 per share on May 24 for a total transaction amount of $2,043,358.

17:02 EDT Cactus appoints Jay Nutt as CFO - Cactus announced the Board of Directors has appointed Jay Nutt as Executive Vice President, CFO and Treasurer, effective June 3. Nutt is a long-tenured financial executive, having served from 2018 until 2021 as Senior Vice President and CFO of ChampionX and its predecessor Apergy, prior to its merger with ChampionX Holding, the upstream energy business of Ecolab. Prior to ChampionX and Apergy, Nutt served in various financial leadership capacities with TechnipFMC plc and FMC Technologies, including as Senior Vice President and Controller from 2017 to 2018, Vice President, Controller and Treasurer from 2015 to 2017, and Vice President and Controller from 2009 through October 2015.

16:59 EDT Matson Chairman Cox sells $1.2M in company shares - Chairman of the Board of Matson, Matthew Cox, disclosed the sale of 9,862 shares of company stock at $120 per share on May 24, for a total transaction amount of $1,183,479

16:56 EDT Ryder CMO sells $816K in common stock - In a regulatory filing, Ryder disclosed that its Chief Marketing Officer Karen Jones sold 6.8K shares of common stock on May 23rd in a total transaction size of $816K.

16:52 EDT Assure Holdings receives notification of delinquency from Nasdaq - Assure Holdings Corp. delinquency in the timely filing of the company's quarterly report on Form 10-Q for the period ended March 31, 2024, the company is out of compliance with Nasdaq Listing Rules and that the Nasdaq Hearings Panel will consider this matter as an additional deficiency, under Listing Rule 5810(d), in their decision regarding the company's continued listing on The Nasdaq Capital Market. Nasdaq's extension notice has no immediate effect on the listing or trading of the company's common stock on the Nasdaq Capital Market. The Notice provides that the company has until May 28, 2024 to present its views with respect to this additional deficiency to the Panel in writing.

16:49 EDT Cronos Group terminates sale-leaseback of Peace Naturals Campus - Cronos Group announced that it has terminated its agreement with Future Farmco Canada , for the sale and leaseback of its property located at 4491 Concession 12 Sunnidale Road, Stayner, Ontario, Canada, L0M 1S0 the "Peace Naturals Campus . The Buyer did not satisfy or waive its due diligence and financing condition by the May 27 deadline, as set forth in the Sale Agreement. All amounts paid by the Buyer as part of a security deposit that were previously held in trust have been returned, in accordance with the Sale Agreement. The Company is continuing to evaluate its strategic options for the Peace Naturals Campus, which may include continuing and expanding operations at the facility.

16:47 EDT American Airlines falls 4% to $12.90 after cutting Q2 earnings guidance

16:39 EDT Shutterstock CFO Jarrod Yahes buys $200K in company shares - The Shutterstock CFO Jarrod Yahes disclosed the purchase of 5,350 shares of company stock at $37.35 per share on May 24, for a total transaction amount of $199,823.

16:33 EDT FMC receives registration in Brazil for Azugro and Ezanya herbicides for cotton - FMC has received registration in Brazil for Azugro and Ezanya herbicides for use in cotton, tobacco and wheat crops. Azugro and Ezanya herbicides are powered by Isoflex active, FMC's brand name for bixlozone. Isoflex active is a novel herbicide when used in cereals and is classified by the Herbicide Resistance Action Committee as a Group 13 herbicide. The two new formulations will provide growers with new tools to effectively manage herbicide resistance across a wide range of agronomic practices. Azugro and Ezanya(R) herbicides offer effective control of key annual grass weeds, including goosegrass, Italian ryegrass (Lolium multiflorum) and some key broadleaf weeds. Azugro herbicide will be available for use in cotton during the 2024 crop season and wheat in 2025, while Ezanya herbicide will be available for use in tobacco during the 2024 crop season. Research on the use of Isoflex active products in additional crops and segments in Brazil is ongoing.

16:32 EDT Kennametal says facility in Rogers, AR, sustained damage from tornado - Kennametal announced that its production facility in Rogers, AR, sustained damage early Sunday morning from a tornado that also affected the larger Rogers community. At the time of the storm, the facility was shut down for the holiday weekend and no employees were onsite. The extent of the damage is currently being assessed. "Our thoughts are with our employees and everyone in the community affected by this storm," said Sanjay Chowbey, incoming President & CEO of Kennametal. "We are working closely with our local team to assess the damage and provide all necessary support and resources to restore operations as quickly as possible."

16:29 EDT Cava Group falls 6% to $77.00 after Q1 results and guidance update

16:21 EDT iKena discontinues IK-930 and reduces workforce by 53%, to review alternatives - Ikena Oncology announced discontinuation of the clinical IK-930 program, the company's TEAD1- selective Hippo pathway inhibitor and continued clinical development of IK-595, a novel MEK-RAF molecular glue. Concurrently, Ikena is evaluating strategic options for both the company and its development pipeline. Based on a review of clinical data to date, available resources, and the company's strategic priorities, the company decided to discontinue development of IK-930. The IK-930 Phase 1 program will begin wind down activities; treatment will continue for patients enrolled to date who have derived benefit. The company will seek strategic options for the program, including potential partners for development of IK-930 in combination with other targeted agents. For IK-595, the first two cohorts in the Phase 1 study of IK-595 in patients with RAS and RAF mutant cancers have cleared; backfilling in select cohorts is planned for the second half of 2024. In connection with the discontinuation of IK-930 development, the company is executing a workforce reduction of approximately 53%. The company has $157M in cash and equivalents as of March 31, 2024; projecting cash and equivalents at December 31 to range from $110M to $120M. Concurrently with the continuation of IK-595 development activities, Ikena has begun to explore, review and evaluate a range of potential strategic options available to the company, including without limitation, an acquisition, merger, reverse merger, sale of assets, strategic partnerships or other transactions

16:21 EDT Palomar raises FY24 adjusted net income view to $122M-128M - Palomar Holdings announced the successful completion of certain reinsurance programs incepting June 1, and increased the Company's full year 2024 adjusted net income guidance. The Company procured approximately $400M of incremental limit to support the growth of its Earthquake franchise. Palomar's reinsurance coverage now extends to $3.06B for earthquake events, $735M for Hawaii hurricane events, and $117.5M for all continental United States hurricane events. The reinsurance program provides ample capacity for the Company's growth in the subject business lines as well as coverage to a level exceeding Palomar's 1:250-year peak zone Probable Maximum Loss. Palomar's per occurrence event retention is $15.5M for hurricane events, reduced from $17.5M the previous year, and $20M for earthquake events, levels that continue to be meaningfully within management's previously stated guideposts of less than one quarter's adjusted net income and less than 5% of the Company's surplus on an after-tax basis. "We are very pleased with the successful June 1 placement and are very grateful for the continued support of our reinsurance and ILS partners," commented Mac Armstrong, Palomar's Chairman and Chief Executive Officer. "Importantly, we renewed our reinsurance program at terms and pricing that were better than our initial expectations and reduced our hurricane event retention. As a result, we are raising our full year 2024 adjusted net income guidance to a range of $122M to $128M from the previously indicated range of $113M to $118M. Palomar's Chief Risk Officer, Jon Knutzen, added, "We are grateful for the broad-based support we received from the reinsurance market. It is a testament to our business mix and risk profile, which has been curated with the goal of delivering more stable, predictable results. We appreciate all our incumbent and new reinsurance partners who have helped us successfully complete our June 1 placement."

16:19 EDT Equity Residential sees second-half EPS and FFO at bottom end of prior outlook - The company states: "Equity Residential announced that members of the Company's senior management team, including the Company's President and CEO, Mark J. Parrell, will participate in meetings with investors and analysts at the Nareit REITWeek 2024 Investor Conference. The Company's Earnings Per Share (EPS) and Funds from Operations(FFO) per share are expected to be in the bottom half of the full year guidance ranges reaffirmed in the Company's Q1 2024 Earnings Release made public on April 23, 2024 due to the litigation reserve adjustment made during the first quarter. Normalized FFO per share, same store revenue and same store net operating income are trending towards the top of their respective full year guidance ranges."

16:17 EDT flyExclusive discloses NYSE notice regarding late filing of quarterly report - The company states: "flyExclusive announced that on May 21, 2024, the Company received notice from NYSE American LLC stating that the Company is not in compliance with Section 1007 of the NYSE American Company Guide because the Company did not timely file its Form 10-Q for the period ended March 31, 2024 with the Securities and Exchange Commission. The Notice has no immediate effect on the listing of the Company's common stock on the NYSE. The Notice informed the Company that, pursuant to NYSE rules, the Company has six months from May 20, 2024, to regain compliance with the NYSE listing standards by filing the Form 10-Q with the SEC. If the Company fails to file the Form 10-Q within that six-month period, the NYSE may grant, in its sole discretion, an extension of up to six additional months for the Company to regain compliance, depending on the specific circumstances. The Notice also notes that the NYSE may nevertheless commence delisting proceedings at any time if it believes, in its sole discretion, that continued listing and trading of the Company's securities on NYSE is inadvisable or unwarranted."

16:14 EDT Sight Sciences publishes SAHARA RCT data demonstrating improved DED symptoms - Sight Sciences announced the publication of the twelve-month results from the SAHARA trial. Patients previously treated with Restasis or cyclosporine ophthalmic emulsion 0.05%, prescription eyedrops, Restasis, had additional clinically meaningful improvements in the signs and symptoms of dry eye disease DED when crossed over to TearCare. These improvements persisted for six months through month twelve without continued Restasis use. "Phase 2 of the RCT again demonstrates the clinical effectiveness of TearCare. It also shows that effectiveness appears to be the same whether or not a patient has had prior treatment with Restasis, demonstrating that similar results could be expected when TearCare is used as a primary or secondary treatment for DED," said Paul Badawi, Co-Founder and Chief Executive Officer of Sight Sciences. "These data demonstrate superior results with a dry eye treatment technology that is not reliant on patient adherence and supports the case for prioritizing interventional eye lid treatment over a prescription-based approach," said Brandon Ayres, MD, Co-Director of the Cornea Fellowship Program at Wills Eye Hospital and a Principal Investigator for the SAHARA RCT.

16:13 EDT Robinhood announces $1B share repurchase program - The board of directors of Robinhood Markets has authorized a $1B share repurchase program, demonstrating management and the board's confidence in Robinhood's financial strength and future growth prospects. Management currently expects to execute this program over a two to three year period starting in Q3 2024, depending on general business and market conditions, and alternative investment opportunities. Management also plans to vary the pace of capital deployment depending on share price. "As our business and cash flow have continued to grow, we're excited to announce a $1 billion share repurchase program to return value to shareholders," said Jason Warnick, Chief Financial Officer of Robinhood. Reference Link

16:11 EDT Farmland Partners names Susan Landi as new CFO - Farmland Partners "announced that Susan Landi has been appointed to the Company's executive team as Chief Financial Officer and Treasurer. Ms. Landi, the senior accounting professional at FPI for over four years, assumed her new role on May 28, 2024. Ms. Landi succeeds James Gilligan, who has stepped down as CFO upon mutual agreement with the Company and will remain as an employee with the Company through June 30, 2024 to ensure a smooth transition."

16:10 EDT Gyre announces addition to Russell 2000 and 3000 Indexes - Gyre Therapeutics announced that it expects to be added to the small-cap Russell 2000 and all-cap Russell 3000 Indexes at the conclusion of the 2024 Russell Indexes annual reconstitution, effective after U.S. market close on June 28 according to a preliminary list of additions posted on May 24. "Gyre's addition to the widely-tracked Russell Indexes represents another important milestone for our company," said Han Ying, Ph.D., Chief Executive Officer of Gyre Therapeutics. "We look forward to the enhanced visibility that inclusion in the Russell Indexes confers as we advance F351 in both the PRC and the United States and aim to create long-term value for our stockholders."

16:08 EDT Staffing 360 Solutions gets Nasdaq notification related to non-timely filing - Staffing 360 Solutions reported that it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market notifying the Company that it is not in compliance with the requirements of Nasdaq Listing Rule 5250(c)(1) as a result of not having timely filed its Quarterly Report on Form 10-Q with the Securities and Exchange Commission for the period ended March 30. Pursuant to the letter, The Nasdaq Hearings Panel will consider the late filing in their decision regarding the Company's continued listing on The Nasdaq Capital Market. Staffing 360 has until June 17 to present its views in writing with respect to the filing deficiency to Nasdaq. Nasdaq's exception to allow the Company to regain compliance, if granted, will be limited to a maximum of 180 calendar days from the initial due date of the Company's Annual Report on Form 10-K, or October 14.

16:07 EDT ICF International awarded $75M contract by EPA - The U.S. Environmental Protection Agency recently awarded a human health and environmental risk assessment contract to global consulting and technology services provider ICF. The single-award indefinite delivery, indefinite quantity contract was awarded by EPA's Office of Research and Development in the first quarter of 2024. This recompete award has a ceiling value of $75M and a term of seven years.

16:06 EDT Fathom names Jon Gwin as COO - Fathom Holdings announced the appointment of Jon Gwin as the company's new COO. Gwin brings over 20 years of leadership experience in legal, compliance, and sales roles within the securities, insurance, mortgage, and real estate industries to his new position as COO at Fathom Holdings.

16:02 EDT Leonardo DRS awarded radar design contract - Leonardo DRS announced that it was awarded a contract from NAVSEA to provide AN/SPQ-9B radar design agent and engineering services. The contract includes options, if exercised, would bring the cumulative value to more than $26 million. Under the contract, DRS will provide system engineering, software development, hardware design, installation, safety, test, product updates, system upgrade and configuration management support.

14:47 EDT Aerwins reports Q1 results, notes 'doubt' on continuing as going concern - Aerwins Technologies disclosed its results for the three months ended March 31, along with which the company noted that as of and for the three months ended March 31, 2024, the company has an accumulated deficit of $63,484,844. On December 27, 2023, the company discontinued the operations of A.L.I. Technologies Inc., a Japanese corporation which is its wholly-owned indirect subsidiary and filed a voluntary bankruptcy petition with the Tokyo District Court, Civil Division 20, the filing noted. A bankruptcy trustee was appointed on January 10, 2024, and proceedings have commenced. "As a result of the filing of the Bankruptcy Proceedings and the January 10 Order, the Company concluded that it no longer controls A.L.I. for accounting purposes as of January 10, 2024, in accordance with U.S. GAAP Accounting Standards Codification 810, and, therefore, A.L.I.'s assets and liabilities have been deconsolidated from the Company's consolidated financial statements prospectively, during the three months ended March 31, 2024. These factors raise substantial doubt on the Company's ability to continue as a going concern," the filing noted. Reference Link

14:12 EDT Capcom's 'Dragon's Dogma 2' draws 3M players since launch - Capcom said its latest role-playing game "Dragon's Dogma 2" has amassed 3M players since its launch earlier this year. Reference Link

13:20 EDT Oshkosh Defense receives $108.9M order to supply additional FMTV A2s - Oshkosh Defense, LLC, an Oshkosh Corporation business, announced that the U.S. Army placed an order for additional Family of Medium Tactical Vehicles A2 and trailers. The order is valued at $108.9M and includes FMTV A2s for U.S. Army modernization initiatives as well as Foreign Military Sales to international partners. "Our continued partnership with the U.S. Army underscores Oshkosh Defense's commitment to equipping our nation's Warfighters with the most advanced tactical wheeled vehicles in support of Army modernization," said Pat Williams, chief programs officer for Oshkosh Defense.

12:40 EDT Montana Technologies Corp trading halted, volatility trading pause

12:04 EDT Loar Holdings falls -7.7% - Loar Holdings is down -7.7%, or -$4.26 to $50.95.

12:02 EDT Hims & Hers rises 12.5% - Hims & Hers is up 12.5%, or $2.10 to $18.98.

12:00 EDT GameStop rises 28.2% - GameStop is up 28.2%, or $5.36 to $24.36.

11:01 EDT Arrow Electronics, SiMa.ai enter distribution agreement in EMEA - Arrow Electronics and SiMa.ai have entered into a strategic collaboration, enabling Arrow to distribute SiMa.ai products in the EMEA region. With this agreement, Arrow and SiMa.ai will jointly market SiMa.ai's offerings and Arrow will serve as the region's exclusive distributor for the SiMa.ai MLSoC, SiMa.ai Palette Software and SiMa.ai Development Kits.

10:37 EDT Logistic Properties of The Americas trading halted, volatility trading pause

10:10 EDT IntelGenx obtains court approval of sale, investment solicitation process - As previously announced on May 17, 2024, IntelGenx Technologies was granted protection pursuant to an initial order issued under the Companies' Creditors Arrangement Act by the Quebec Superior Court. The Initial Order appointed Ernst & Young Inc. as monitor and authorized interim debtor-in-possession financing provided by atai Life Sciences AG in order to allow the Company to continue its operations during the restructuring process and implement the necessary restructuring measures. On May 27, 2024, IntelGenx obtained an order from the Court approving the implementation of a sale and investment solicitation process intended to generate interest in either the business or the assets of IntelGenx, or in a recapitalization of IntelGenx, with the goal of implementing one or more transaction. The SISP Approval Order provides that the SISP will be conducted by the Monitor. As part of the SISP Approval Order, the Court also approved the agreement of purchase and sale between IntelGenx, as vendor, and atai Life Sciences AG, as purchaser, solely for the purpose of constituting the "stalking horse" bid under the SISP. The Stalking Horse Bid establishes a baseline price and deal structure for the solicitation of superior bids from qualified interested parties and provides certainty that a going-concern solution for the business of IntelGenx has already been identified. All qualified interested parties will be provided with an opportunity to participate in the SISP. The SISP is intended to solicit interest in and opportunities for a broad range of executable transaction alternatives involving the business and assets of IntelGenx, through one or more sales or partial sales of all, substantially all, or certain portions of the business and assets, and/or an investment in, restructuring, recapitalization, refinancing or other form of reorganization of IntelGenx or its business. The SISP will be conducted as a two-phase process with the Phase 1 Non-Binding LOI Submission Deadline set for 5:00 p.m. on July 15, 2024.

10:04 EDT Bakkt falls -7.1% - Bakkt is down -7.1%, or -$1.24 to $16.15.

10:02 EDT GameStop rises 15.3% - GameStop is up 15.3%, or $2.90 to $21.90.

10:01 EDT Oklo rises 18.9% - Oklo is up 18.9%, or $1.92 to $12.06.

09:52 EDT IZEA adopts limited-duration stockholder rights plan - IZEA Worldwide's Board of Directors have adopted a limited duration stockholder rights plan under which stockholders will receive rights to purchase a new series of preferred stock in certain circumstances. The Board of Directors adopted the Rights Plan following the rapid accumulation of stock by a single investor. The Rights Plan is designed to protect all stockholder interests by reducing the likelihood that any person or group could gain control of the Company without appropriately compensating Company stockholders for control. The Rights Plan is not intended to prevent or interfere with any action with respect to the Company that the Board determines to be in the best interests of stockholders. Instead, it will position the Board to fulfill its fiduciary duties on behalf of all stockholders by providing the Board with time to make informed decisions about significant accumulations of Company common stock and attempts to control the Company. The Rights Plan does not preclude the Board from considering an offer that recognizes the full value of the Company. The Rights Plan encourages anyone seeking to gain control of the Company to negotiate directly with the Board. The Rights Plan is similar to plans adopted by other publicly traded companies. While the Rights Plan is effective immediately, the rights will be exercisable only if a person or group acquires beneficial ownership, as defined in the Rights Plan, of 15% or more of the Company common stock, subject to certain exceptions. Any shareholders with beneficial ownership of 15% or more of the Company's outstanding common stock prior to this announcement are generally grandfathered at their current ownership levels but are not permitted to increase their ownership without triggering the Rights Plan. Subject to the terms of the Rights Plan, if the rights become exercisable, the ownership of any Acquiring Person will likely be significantly diluted.

09:51 EDT GameStop rises 18.0% - GameStop is up 18.0%, or $3.42 to $22.42.

09:49 EDT Ryde Group Ltd trading resumes

09:48 EDT Yatsen falls -6.5% - Yatsen is down -6.5%, or -22c to $3.18.

09:46 EDT SINTX Technologies Inc trading resumes

09:38 EDT Elliott discloses '$2.5B-plus' Texas Instruments position, proposes new strategy - Elliott Investment Management, which manages funds that together have an investment of more than $2.5B in Texas Instruments, discussed a letter the firm sent to the board of directors of Texas Instruments, noting that in the letter Elliott proposed that Texas Instruments "adopt a dynamic capacity-management strategy and introduce a free cash flow per share target of $9.00+ in 2026." In doing so, Elliott believes that, TI can re-establish itself as a "compelling" investment, also benefitting from "a strong cyclical recovery in the analog market." "TI's shareholder returns have lagged peers consistently over a multi-year period," Elliott wrote, "despite TI's reputation as one of the best-managed semiconductor companies with strong growth prospects and competitive advantages." Elliott continued: "Our diagnosis is simple: Investors are concerned that TI appears to have deviated from its longstanding commitment to drive growth of free cash flow per share." Elliott concluded that it believes "in the strategic merit of American semiconductor manufacturing leadership," and that "TI is positioned as the only analog company with proven industry leadership and proven technology to achieve this goal at scale." Reference Link

09:26 EDT Inspira Technologies' ART100 receives FDA 510(k) clearance - Inspira Technologies has received notification of 510(k) class II clearance from the FDA for its Inspira ART100, a cardiopulmonary bypass system.

09:14 EDT NextSource Materials appoints Hanre Rossouw as CEO - NextSource Materials confirms changes to its top management team ahead of the next phase of the Company's global growth strategy. The Board of NextSource is pleased to announce the appointment of Hanre Rossouw as President and CEO effective November 1st, 2024, with Hanre initially joining the Board as a Director from September 1st, 2024. Hanre joins NextSource from his role as Executive Director and CFO of Sasol Limited with extensive experience in the global natural resources industry over the last 25 years. Effective Nov. 1, Craig Scherba, current NextSource President and CEO, will continue as a Director and Chief Development Officer of NextSource to focus on developing strategy, managing offtake negotiations and expanding the Company's OEM relationships around the world.

09:11 EDT GameStop up 26% in pre-market trading at $23.97 - Shares of GameStop are up 26% or $4.97 in pre-market trading at $23.97. On Friday following the market close, the company had announced that it has completed an 'at-the market' equity offering program with gross proceeds of about $933M.

09:06 EDT Xylo Technologies says Metagramm completes development of Bubbl - Xylo Technologies announced that Metagramm Software completed development of Bubbl, an advanced writing tool utilizing Machine Learning, Natural Language Processing, Artificial Intelligence and Deep Learning technologies. Bubbl offers an innovative document writing and rewriting solution that enables content creation with personalized and customized text tailored to the user's unique way of expression-unlike widely used AI tools that often produce machine-like results. Users can also request their desired content to be translated and edited into other languages. Metagramm plans on launching the first version, for selected users, during the third quarter of 2024.

09:05 EDT Patria Investments receives approvals for transfer of Credit Suisse funds - Patria Investments announced that it has received all necessary REIT shareholders approvals for the transfer of management of Credit Suisse's Real Estate funds in Brazil with approximately $2.4 billion of Fee Earning AUM. Following the transfer of the funds, which is expected to take place in stages and be completed by August 30th, Patria's Real Estate business will total more than $6 billion in Fee Earning AUM, up from less than $700 million at the time of its 2021 IPO, and the transaction brings Patria's permanent capital to approximately 20% of total Fee Earning AUM, compared to virtually nil at the time of the IPO.

09:04 EDT Semler Scientific board adopts bitcoin as its primary treasury reserve asset - Semler Scientific announced that its board of directors has adopted bitcoin as its primary treasury reserve asset. In addition, Semler Scientific announced that it has purchased 581 bitcoins for an aggregate amount of $40M, inclusive of fees and expenses.

09:03 EDT Puma Biotechnology to join Russell 3000 Index - Puma Biotechnology is set to join the broad-market Russell 3000 Index at the conclusion of Russell Investments' annual reconstitution of its comprehensive set of U.S. and global equity indexes on June 28 and effective after U.S. markets open on July 1, according to a preliminary list of additions posted on May 24.

09:02 EDT Pagaya set to join Russell 2000 Index - Pagaya Technologies announced that as part of the annual reconstitution of the Russell stock indexes, Pagaya is set to join the Russell 2000 ndex and the broad-market Russell 3000 Index, effective at the open of US equity markets on Monday, July 1st. A preliminary list of Russell 3000 Index additions, including Pagaya, was posted by FTSE Russell on May 24.

09:02 EDT Castor Maritime completes sale of M/V Magic Horizon - Castor Maritime completed the previously announced sale of the M/V Magic Horizon, a 2010-built Panamax bulk carrier vessel, for a price of $15.8 million, by delivering the vessel to its new owner. The Company expects to record a net gain of approximately $4.6 million from the above-mentioned sale, excluding any transaction-related costs, during the second quarter of 2024.

08:57 EDT InspireMD presents one-year follow-up results from C-GUARDIANS IDE trial - InspireMD announced the presentation of positive one-year outcomes from its C-GUARDIANS IDE clinical trial of the CGuard Carotid Stent System for the treatment of carotid artery stenosis at this year's Leipzig Interventional Course, LINC, 2024, which is being held May 28-31, in Leipzig, Germany. Marvin Slosman, chief executive officer of InspireMD, stated, "We are very pleased to have such a significant presence at this year's LINC conference, highlighted by a presentation of the primary endpoint results from our C-GUARDIANS clinical study. The independently adjudicated major adverse event rates through one-year are the lowest reported to date from any carotid stent or embolic protection device pivotal trial. With these data in-hand, we now have line of sight to a PMA application in the back half of this year, with preparation ongoing for a robust U.S. commercial launch in the first half of 2025, if approved. In addition to these results, we continue to be enthusiastic about our plans to introduce both CAS and TCAR solutions serving the broadest community of specialists serving the carotid revascularization market with the best implant in CGuard Prime."

08:44 EDT PayPal announces new leadership appointments for new ad platform - PayPal (PYPL) announced new leadership appointments that it says "will drive the creation of a new advertising platform and strengthen the company's consumer value proposition." Mark Grether will join on May 28 as SVP, General Manager, PayPal Ads, and John Anderson has joined as SVP, General Manager, Consumer Group. Grether and Anderson will report to Diego Scotti, EVP, General Manager, Consumer Group and Global Marketing & Communications. Grether joins PayPal from Uber (UBER), where he was the Vice President, General Manager of Uber Advertising. Anderson joins PayPal from Plaid, where he was Head of Product and Payments. "Commerce and advertising are deeply connected, and we believe that the advertising platform we are building at PayPal will become a must-use marketing channel for merchants big and small. I'm thrilled to have Mark join our team and lead this important work," said Scotti.

08:42 EDT Jaguar Health anounces results of investigator-initiated trial of crofelemer - Jaguar Health announced that the results of a third-party, investigator-initiated study of crofelemer, Napo's novel plant-based prescription drug, show that twice daily oral administration of crofelemer led to a statistically meaningful reduction of abdominal pain and discomfort and improved stool consistency in functional diarrhea patients when compared to placebo. The study investigators are preparing an abstract on the study for submission to a peer-reviewed journal later this year. Functional diarrhea, defined as chronic diarrhea for more than 6 months, is a common diagnosis without effective treatments. It is a functional gastrointestinal disorder, meaning that it occurs without any other known signs of disease, injury, or structural problem. A global survey by the Rome Foundation of 73,000 adults in 33 countries found that functional diarrhea had a prevalence of 4.7%. Crofelemer is a novel, oral plant-based medicine purified from the red bark sap, also referred to as "dragon's blood," of the medicinal Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for Indigenous communities.

08:40 EDT Sight Sciences announces publication of analysis from ROMEO study - Sight Sciences announced the results as published in the journal Clinical Ophthalmology of a new analysis of the ROMEO study data. This new analysis evaluated the association between the severity of glaucoma and the intraocular pressure and medication outcomes for patients treated with the OMNI Surgical System. OMNI enables a procedure intended to restore aqueous outflow of glaucomatous eyes by addressing the three areas of outflow resistance associated with the disease. The findings suggest that ab interno canaloplasty coupled with trabeculotomy using OMNI was as effective at lowering IOP and reducing medication usage in advanced glaucoma patients as it was in mild and moderate glaucoma patients. This data challenges the belief that advanced disease stage is a barrier to successful treatment outcomes for minimally invasive glaucoma surgery. ROMEO was an Institutional Review Board approved retrospective case series conducted at eleven ophthalmology practices in the United States. Participants were mainly primary open-angle glaucoma patients who had undergone the implant-free OMNI procedure, which has been cleared by the FDA for canaloplasty followed by ab interno trabeculotomy to reduce intraocular pressure in adult patients with primary open-angle glaucoma, either combined with cataract surgery or as a standalone procedure. Eyes were categorized based on visual field mean deviation, with participants assigned to a group with severity rated as mild, moderate or advanced. The study compared outcomes at 12 months. Key findings reported in the study include: Significant reductions in both IOP and IOP-reducing medications were observed. The majority of eyes experienced a reduction in IOP at Month 12, with most achieving levels of 18 mmHg or less. The percentage of IOP reduction was consistent across severity groups, with month 12 mean IOP ranging between 14 mmHg and 16 mmHg. Medication reductions were observed across all severity groups, with the majority of patients showing a reduction of at least 1 medication, indicating the effectiveness of the treatment approach. Regression analysis found no significant relationship between month 12 IOP and visual field loss, suggesting treatment outcomes were consistent irrespective of disease severity.

08:39 EDT Riot Platforms proposes to buy Bitfarms for $2.30 per share - Riot Platforms (RIOT) announced that it has made a proposal to the Bitfarms Board of Directors to acquire all of the outstanding shares of Bitfarm (BITF) at a price o $2.30 per Bitfarms common share . Riot also announced that it has accumulated a 9.25% stake in Bitfarms to become Bitfarms' largest shareholder. The Proposal represents a 24% premium to Bitfarms' one-month volume-weighted average share price as of May 24 Further, it represents a 20% premium to Bitfarms' share price on April 19 the last day of trading prior to Riot's initial proposal to the Bitfarms Board. The Proposal represents approximately $950M in total equity value. The consideration offered to Bitfarms' shareholders under the Proposal consists of cash and Riot common stock and would result in Bitfarms' shareholders owning up to approximately 17% of the combined company. This cash and stock Proposal would provide Bitfarms' shareholders with a substantial premium and immediate cash value, as well as significant potential for future value creation through participation in a financially and commercially stronger company with a well-defined strategy, led by an established and proven management team. This cash and stock Proposal would provide Bitfarms' shareholders with a substantial premium and immediate cash value, as well as significant potential for future value creation through participation in a financially and commercially stronger company with a well-defined strategy, led by an established and proven management team.

08:38 EDT CompoSecure showcases Arculus Web3 payment capabilities at Consensus - CompoSecure announced expanded capabilities that enable Web3 payments for everyday purchases through the convenience of a metal card. Using these capabilities, consumers can have the flexibility to securely self-custody their digital assets and make those stablecoins and other digital assets spendable at the point of sale with a simple tap-to-pay. The Arculus Web3 payment capabilities will be demonstrated in the Arculus booth May 29-31 at Consensus by CoinDesk in Austin, TX. The new Arculus capabilities can dramatically simplify the process, allowing merchants to instantly accept purchases with debit, credit and cryptocurrencies. Consumers will be able to pay just like they do with a traditional payment card. With the integration of the new Arculus capabilities, consumers will be able to use digital currency to pay wallet-to-wallet directly to the merchant at supported PoS terminals or over traditional payment card rails.

08:38 EDT Ispire Technology signs exclusive distribution deal in South Africa - Ispire Technology announced an exclusive distribution deal with Dank Pack, South African supplier of cannabis product packaging, accessories, dispensary supplies and production and manufacturing equipment. Under the agreement, Ispire is entering the South African cannabis market by supplying Dank Pack with a host of vapor products and accessories.

08:37 EDT Sera Prognostics set to be added to Russell 2000, 3000 indexes - Sera Prognostics announced that it has been added to the preliminary list of the Russell Small-Cap 2000 and Russell 3000 indexes as part of the Russell indexes annual reconstitution.

08:36 EDT Xenon Pharmaceuticals presents data from Phase 2 X-Nova trial - Xenon Pharmaceuticals announced data presentations highlighting azetukalner, XEN1101, clinical data in major depressive disorder, MDD, at the American Society of Clinical Psychopharmacology, ASCP, 2024 Annual Meeting in Miami, FL. Summary of Efficacy Data: The primary endpoint of the study was a change in the Montgomery-Asberg Depression Rating Scale, or MADRS, at week 6. The mean reduction was 13.90 in the placebo group, 15.61 in the 10 mg group and 16.94 in the 20 mg group. A clear dose response and a clinically meaningful, but not statistically significant. At week 1, the mean reduction in MADRS score from baseline was significantly different between placebo and azetukalner 20 mg groups, demonstrating early onset of efficacy. The mean reduction in the Hamilton Depression Rating Scale, or HAM-D17, score from baseline to week 6 was significantly different between placebo and azetukalner 20 mg groups. The mean reduction in the Snaith-Hamilton Pleasure Scale, or SHAPS, score from baseline to week 6 was significantly different between placebo and azetukalner 20 mg groups. There were no statistically significant differences in change from baseline BAI total scores to week 6 between placebo and azetukalner groups. Statistical significance was achieved in reporting of at least minimally improved symptoms of depression as assessed by physicians using the Clinical Global Impression of Improvement in the azetukalner 20 mg group compared to placebo. Summary of Safety and Tolerability Data: Azetukalner was well tolerated with a low incidence of treatment-emergent adverse events, and no serious TEAEs were reported in either dose group.

08:36 EDT NRx Pharmaceuticals' NRX-101 eeduces suicidality in bipolar depression trial - NRx Pharmaceuticals announced presentation of its Phase 2b/3 trial of NRX-101 at the American Society of Clinical Psychopharmacology in Miami Beach. Conclusions of the poster include: NRX-101 and lurasidone both demonstrated greater than 50% response for treating bipolar depression with no difference seen on primary efficacy endpoint; a clinically meaningful difference was observed on both primary and secondary safety endpoints favoring NRX-101; NRX-101 was associated with 58% relative reduction in time to sustained remission from suicidality; NRX-101 was associated with a relative 76% reduction in symptoms of akathisia - a side effect in which patients are agitated and frequently experience involuntary movement - vs. lurasidone that was sustained over 42 days; akathisia was seen in 2% of participants treated with NRX-101 vs. 11% treated with lurasidone. No treatment-related serious adverse event was observed in either group. The company believes that NRX-101 has potential to become a standard of care drug for treating bipolar depression. This study represents the second trial conducted under FDA Good Clinical Practices guidelines to demonstrate large and meaningful advantages of NRX-101 vs lurasidone on akathisia and suicidality and clears the path for a registration trial of NRX-101 to treat bipolar depression together with earlier accelerated approval for those with akathisia. To the company's knowledge, this trial and its prior STABIL-B study represent the only clinical trials in which an oral antidepressant has been demonstrated to cause meaningful reductions in suicidality and akathisia.

08:35 EDT Bannix Acquisition receives Nasdaq notice of non-compliance - Bannix Acquisition received a letter from the Listing Qualifications Department of the Nasdaq Stock Market advising the Company that the Company does not comply with NASDAQ's Listing Rule 5250(c)(1) for continued listing because NASDAQ had not received the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2024 and because the Company remains delinquent in filing its Form 10-K for the fiscal year ended December 31, 2023. In accordance with Nasdaq letter dated April 24, 2024, the Company has until June 24, 2024 to submit a plan to regain compliance with respect to these delinquent reports. The Company is working diligently to complete the Form 10-K and the Form 10-Q. If the Company is unable to file the Form 10-K and the Form 10-Q by June 24, 2024, it intends to file a plan to regain compliance with NASDAQ. This notification has no immediate effect on the listing of the Company's securities on NASDAQ. There can be no assurance, however, that the Company will be able to file Form 10-K and Form 10-Q by June 24, 2024, regain compliance with the listing requirements discussed above or otherwise satisfy the other NASDAQ listing criteria.

08:34 EDT Atossa Therapeutics announces support for Phase 2 SMART study - Atossa Therapeutics announced support for a new Phase 2 study designed to validate an innovative, artificial intelligence driven, breast cancer risk assessment model. The SMART study will test an individualized, imaging-based screening model designed to identify women with the highest risk of developing breast cancer in the next two years. If the model is validated for therapeutic use, it could serve as the foundation for a future, Phase 3, trial investigating (Z)-endoxifen in the breast cancer prevention setting. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. The SMART study is expected to enroll 70,000 women who will join following their regularly scheduled bi-annual mammogram, the cost of which is covered by the nationalized healthcare system in Sweden. Mammogram results and additional assessment data will be analyzed by a proprietary algorithm known as the Profound Artificial Intelligence Risk Assessment Model, which will determine each participant's risk of developing breast cancer in the next two years. The approximately 20% of women who have the highest risk of developing breast cancer in the next two years will be randomized into two arms. In the intervention arm, the approximately 7,000 women at highest risk will have a contrast enhanced mammogram. CEM has proven to better identify cancers that were missed on the regular mammogram because of dense breast tissue. Participants in the control arm will screen according to current guidelines, that is, return in two years for their next regularly scheduled mammogram. The study will measure how many women across both arms develop breast cancer over the next two years, which will determine the predictive power of the proprietary algorithm.

08:32 EDT Weatherford awarded framework extension with Equinor - Weatherford International (WRFD) has been awarded a two-year frame agreement extension with Equinor (EQNR) for the delivery of completions, liner-hangers, and slot recovery services. To deliver on this scope, Weatherford will offer its Accuview downhole monitoring solutions with the AlphaV next-generation whipstock system building on our track record of enhancing operational efficiency and reducing rig time. Notably, in 2023, Weatherford successfully introduced AlphaV, enabled by the Accuview platform in the North Sea for Equinor. This deployment eliminated the need for a dedicated wellbore preparation run, saving cost and improving operation efficiency through remote monitoring capabilities. Combining these proprietary technologies with those acquired from the Ardyne portfolio, Weatherford recently executed a slot recovery operation, delivering further cost and operational enhancements for Equinor. Through this extension, Equinor also gains access to Weatherford's ForeSite sense optical reservoir monitoring solution alongside a comprehensive array of completion solutions. Weatherford's unique offering allows for integrating various measurement types in a single fiber optic cable, simplifying the downhole architecture and facilitating reliable reservoir monitoring as a means to production optimization.

08:29 EDT Ameresco begins construction on $33M ESPC - Ameresco announced that construction is underway for a $33M Energy Savings Performance Contract, or ESPC, at the U.S. National Archives and Records Administration, or NARA, sites in College Park, Maryland, and Washington, DC. The project is designed to enhance energy efficiency across NARA's facilities, leveraging Ameresco's innovative solutions to achieve significant cost savings and environmental benefits.

08:20 EDT Ensysce Biosciences regains compliance with Nasdaq - Ensysce Biosciences has received notice on May 24, 2024 from The Nasdaq Stock Market that the Company has demonstrated compliance with the equity requirement in Listing Rule 5550(b)(1), as described in the Hearing Panel's decision dated February 26, 2024, as amended. As a result, Ensysce common stock will continue trading on Nasdaq's Capital Market tier.

08:19 EDT Diamondback Energy announces sale of WTG Midstream to Energy Transfer - Diamondback Energy (FANG) announced the sale of WTG Midstream Holdings to Energy Transfer LP (ET) resulting in total pre-tax consideration net to Diamondback of approximately $375 million, subject to customary closing conditions and adjustments. Consideration for the transaction will consist of a mix of cash and ET common units. The transaction is expected to close in the third quarter of 2024. "We would like to congratulate Stonepeak and the WTG team on this fantastic outcome," stated Travis Stice, Chairman and Chief Executive Officer of Diamondback. "Not only has our partnership generated an outsized economic return, but WTG's gas gathering and processing system continues to support Diamondback's substantial activity on our dedicated acreage. We are excited to further expand our relationship with Energy Transfer and expect a smooth operational transition."

08:16 EDT 1847 Holdings provides update on pending strategic transactions - 1847 Holdings provided a business update on its pending strategic transactions. Ellery Roberts, CEO of 1847 Holdings, commented, "Following a strong first quarter, in which we achieved solid revenue growth and successfully divested Asien's Appliance, I am pleased to report we are making continued progress on a series of additional strategic initiatives expected to significantly enhance shareholder value. As an example, we are rapidly advancing towards finalizing our definitive agreement to acquire a prominent millwork, cabinetry, and door manufacturer, which generated very significant EBITDA in 2023. Through the combination of this and other planned activities, we expect to significantly lower our leverage ratio via an increase in net EBITDA relative to outstanding debt. In turn, we plan to accelerate our repayment of debt, extend the duration of remaining indebtedness, as well as eliminate any equity-linked aspects of repayment. As a result, we expect 1847 will be in a stronger financial position, generating meaningful cash flow with an enhanced balance sheet and capital structure. We expect to complete the outstanding transactions in the near term and look forward to providing updates as developments unfold."

08:15 EDT Aquestive Therapeutics to present Anaphylm sublingual film PK, PD data - Aquestive announced that two encore poster presentations highlighting the positive pharmacokinetic and pharmacodynamic data from two completed clinical studies for Anaphylm sublingual film will be presented at the Eastern Allergy Conference. Taking place from May 30 through June 2, 2024, in Palm Beach, Florida, EAC features the most current information from the field's top experts on Allergy, Asthma and Immunology. Anaphylm is the Company's first and only orally administered epinephrine prodrug product candidate under development for the treatment of severe life-threatening allergic reactions, including anaphylaxis. "As we continue to highlight the positive results from our Anaphylm clinical trials, we are pleased to present at a conference that brings together so many renowned leaders in the allergy space," said Dan Barber, President and Chief Executive Officer of Aquestive. "Anaphylm has the potential to transform the treatment of severe allergic reactions, including anaphylaxis. Our recently completed Phase 3 pivotal trial met all its expected endpoints and the remaining pre-submission studies are underway as we target filing an Anaphylm New Drug Application with the FDA by the end of 2024."

08:13 EDT BriaCell announces clinical supply agreement with BeiGene - BriaCell Therapeutics (BCTX) announces a clinical supply agreement with BeiGene (BGNE) to evaluate the safety and efficacy of Bria-OTS, BriaCell's next generation immunotherapy, in combination with BeiGene's anti-PD-1 antibody, tislelizumab, for the treatment of advanced heavily pretreated metastatic breast cancer. "We are extremely excited about partnering with BeiGene on this novel immunotherapy approach with planned expansion to prostate and other cancers," stated Dr. William Williams, BriaCell's President & CEO. "This agreement marks another positive milestone for BriaCell in our commitment to transform cancer care." The limited access Phase 1/2 clinical trial will initially evaluate the safety and efficacy of Bria-OTS alone in breast cancer and later in combination with tislelizumab. BriaCell also plans to evaluate Bria-OTS in prostate and other cancers.

08:12 EDT 1847 says 'making continued progress' on strategic initiatives - 1847 Holdings provided a business update on its pending strategic transactions. Ellery Roberts, CEO of 1847, commented, "Following a strong first quarter, in which we achieved solid revenue growth and successfully divested Asien's Appliance, I am pleased to report we are making continued progress on a series of additional strategic initiatives expected to significantly enhance shareholder value. As an example, we are rapidly advancing towards finalizing our definitive agreement to acquire a prominent millwork, cabinetry, and door manufacturer, which generated very significant EBITDA in 2023. Through the combination of this and other planned activities, we expect to significantly lower our leverage ratio via an increase in net EBITDA relative to outstanding debt. In turn, we plan to accelerate our repayment of debt, extend the duration of remaining indebtedness, as well as eliminate any equity-linked aspects of repayment. As a result, we expect 1847 will be in a stronger financial position, generating meaningful cash flow with an enhanced balance sheet and capital structure. We expect to complete the outstanding transactions in the near term and look forward to providing updates as developments unfold."

08:11 EDT Mainz Biomed to present new pooled colorectal cancer screening data - Mainz Biomed announces its participation in the American Society of Clinical Oncology, ASCO, 2024 Annual Meeting. This prestigious conference will be held from May 31 to June 4, 2024, in Chicago, Illinois, and online, serving as a leading forum for the latest developments in oncology. The combined analysis from the ColoFuture and eAArly DETECT studies represents the largest dataset to date, with 690 subjects including previously unexamined and unreported subjects enrolled across 30 clinical sites. These studies were designed to assess the performance of a novel stool-based approach that combines mRNA signatures and the Fecal Immunochemical Test with an AI-generated algorithm to improve diagnostic performance for detecting colorectal cancer and advanced precancerous lesions.

08:10 EDT Outlook Therapeutics receives European Commission MA for LYTENAVA - Outlook Therapeutics announced that the European Commission has granted Marketing Authorization, MA, for LYTENAVA, an ophthalmic formulation of bevacizumab for the treatment of wet AMD in the EU. LYTENAVA is the first and only authorized ophthalmic formulation of bevacizumab for use in treating wet AMD in the EU. "This is a landmark milestone for us. We are extremely pleased to receive Marketing Authorization for LYTENAVA in the EU and are moving toward our potential first commercial launch in an EU Member State in the first calendar quarter of 2025. The EU represents the second largest wet AMD market in the world, and we look forward to continuing our efforts to bring to the EU market the first and only on-label, ophthalmic bevacizumab for the treatment of wet AMD. We are incredibly grateful to all the patients, researchers, clinical sites and the European Medicines Agency for the research, drug development, and regulatory efforts that led to this approval," commented Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics.

08:09 EDT Xiao-I-s Knowledge Management system selected by telecom company - Xiao-I has signed a contract with a telecommunications company in a special administrative region to introduce Xiao-I's Intelligent Knowledge Management system. The System is a solution designed to transform how the telecommunications industry manages, processes, and utilizes knowledge, leveraging the foundational capabilities of the Hua Zang Large Language Model. The System streamlines content editing processes, supports intelligent knowledge operations, improves the approval and review processes, and includes advanced search capabilities for comprehensive retrieval of knowledge.

08:08 EDT ParaZero receives purchase order for advanced safety systems - ParaZero Technologies has received a purchase order from a leading UAE-based company specializing in heavy-lift cargo drones and advanced air mobility platforms. This partnership involves the development and delivery of customized safety systems for the partner's heavy-lift cargo drones. ParaZero has secured a deal to develop and provide a custom solution, based on its SafeAir systems, enhancing the safety of their cutting-edge unmanned aircraft systems and electric vertical takeoff and landing aircraft.

08:09 EDT Norfolk Southern names Claude Mongeau chair of the board of directors - Norfolk Southern's (NSC) Board of Directors has unanimously appointed Claude Mongeau, former CEO of Canadian National Railway Company (CNI), as the independent chair of the board, effective immediately. Mongeau will serve as chair of the Executive Committee and resign from his positions on the Human Capital Management and Compensation and Safety Committees.

08:06 EDT AbbVie to present new antitumor data from ADC platform - AbbVie announced that new data from its antibody-drug conjugate - ADC - platform will be showcased across three oral presentations at the upcoming ASCO Annual Meeting. ADCs are designed to deliver cancer cell death-inducing agents called 'payloads' to the tumor. Data from the dose-escalation and colorectal cancer - CRC - dose-expansion cohort of an ongoing first-in-human Phase 1 study of ABBV-400, a c-Met directed ADC, to be presented in an oral presentation, data show that among 122 heavily pre-treated advanced CRC patients, promising antitumor activity was observed at 2.4 and 3.0 mg/kg doses administered once every 3 weeks, with confirmed objective response rate of 18% and 24% respectively. In patients with higher c-Met expression, ORR was enriched to greater than35% at doses greater than or equal to2.4 mg/kg. The most common Grgreater than or equal to3 treatment-emergent adverse events were anemia - 35% -, neutropenia - 7% - and febrile neutropenia - 6% -. TEAEs leading to discontinuation occurred in 25 - 20.5% - patients. ABBV-400 is also being evaluated in a Phase 1b basket study in advanced solid tumors as a monotherapy and a Phase 2 study in second line metastatic CRC in combination with fluorouracil, folinic acid, and bevacizumab. In addition, early data from the monotherapy dose escalation part of a first-in-human study of ABBV-706, a directed ADC, demonstrate that overall confirmed objective response rate was 43.8%. The ongoing study is evaluating ABBV-706 as monotherapy or in combination in patients with advanced solid tumors. AbbVie will also present data from the primary analysis of the Phase 2 LUMINOSITY non-small cell lung cancer - NSCLC - trial evaluating telisotuzumab vedotin in advanced NSCLC. AbbVie previously announced positive topline results from the study in November 2023.

08:05 EDT Corcept Therapeutics announces Phase 3 GRACE trial meets primary endpoint - Corcept Therapeutics announced that GRACE, the Phase 3 trial of its proprietary selective cortisol modulator relacorilant in patients with hypercortisolism, met its primary endpoint. The GRACE study has two parts. On April 22, Corcept announced that patients in GRACE's initial, open-label phase exhibited clinically meaningful and statistically significant improvements in hypertension, hyperglycemia and other symptoms experienced by patients with Cushing's syndrome. Patients who exhibited pre-specified improvements in hypertension, hyperglycemia or both were given the opportunity to enter the trial's randomized, double-blind withdrawal phase, in which half of the patients continued to receive relacorilant and half received placebo, for 12 weeks. GRACE met its primary endpoint of loss of blood pressure control in the randomized withdrawal phase among patients receiving relacorilant as compared to placebo. Consistent with its known safety profile, relacorilant was well-tolerated in both phases of GRACE, with no differences in the randomized withdrawal phase between the relacorilant and placebo groups. Additional data will be presented at the Endocrine Society annual meeting in Boston and the Heart in Diabetes conference in Philadelphia. The company expects to submit its New Drug Application in the third quarter.

08:04 EDT PetMed Express appoints Carla Dodds as CMO - PetMed Express announced the appointment of Carla Dodds as Chief Marketing Officer. As CMO, Dodds will be responsible for leading PetMeds' integrated marketing strategy including brand and content, digital and lifecycle marketing, co-op media, customer acquisition and retention, customer insights and market research, social media and corporate communications. She brings extensive experience in leadership roles encompassing marketing, strategy and operations for major global companies including Walmart, MasterCard, Curacao, Omnilife-Chivas Group, and Penske Media Corporation.

08:03 EDT LivePerson names Sandy Hogan as CRO - LivePerson announced the appointment of Sandy Hogan as Chief Revenue Officer. Hogan joins the company as part of its go-to-market transformation strategy aimed at generating even more value for its enterprise customers. Prior to LivePerson, she served as Chief Revenue Officer for SADA, where she led the largest go-to-market transformation in the company's history.

08:02 EDT Definitive Healthcare appoints Kevin Coop as CEO - Definitive Healthcare announced that its Board of Directors has appointed Kevin Coop as the Company's next CEO and as a member of the Board of Directors, each effective June 24, 2024. Mr. Coop succeeds Jason Krantz, founder and Executive Chairman, who has been serving as Interim CEO since January 2024. Mr. Krantz will continue to serve on the Board of Directors as Executive Chairman after the CEO transition. Coop joins Definitive Healthcare from DailyPay, Inc., a leading financial services work technology company, where he served as CEO and a member of the board of directors.

07:53 EDT Vista Outdoor rejects unsolicited indication of interest from MNC Capital - Vista Outdoor announced that its board of directors, following consultation with its financial and legal advisors, has rejected the unsolicited indication of interest received from MNC Capital on March 25 pursuant to which MNC expressed interest in acquiring Vista Outdoor in an all-cash transaction for $37.50 per Vista Outdoor share. The board issued a letter to MNC which is reproduced below. The board believes there is significantly more value in the Revelyst business than MNC credited in its indication of interest. The company expects to drive a $100M improvement in adjusted EBITDA by FY27. Vista Outdoor is also on its way to deliver on the GEAR Up initiative and expects to deliver $25M-30M in savings while doubling standalone adjusted EBITDA in FY25. Additionally the company's strong cash generation and pay down of total debt by $115M in Q4 of FY24 reinforces the fact that the MNC indication of interest undervalues the Revelyst business. The board continues to recommend the acquisition of The Kinetic Group by Czechoslovak Group a.s.

07:44 EDT ARway.ai closes acquisition of Map Dynamics - ARway.ai acquired Map Dynamic in exchange for 4 million shares valued at over $1M based on May 17th's closing price of $0.26/share. The shares are subject to a lockup of 4 months and 1 day ending September 29th 2024. Map D is a real world Mapping Software company that has over 400 clients generating $1.2 million in annual revenue with $250,000 in EBITDA over the past 12 months ending in March, 2024. Map Dynamics is a well-established event technology company wholly owned by Nextech3D.ai (NEXCF). This strategic acquisition combines two interactive mapping platforms expected to fast track ARway's product development roadmap and add significant new revenue channels and growth opportunities as both companies focus exclusively on mapping.

07:42 EDT Rekor Systems introduces new cybersecurity capabilities - Rekor Systems has further invested in its commitment to safeguarding the nation's transportation infrastructure through the addition of AI-based dynamic cybersecurity monitoring, detection, and response to its suite of capabilities. The company's next-generation AI cyber-secure roadside Edge-based systems now integrate real-time threat detection, dynamic monitoring, anomaly analysis, and automated incident response capabilities. This enhances the holistic approach from Edge computing to Cloud that Rekor has taken to provide sophisticated AI, data, and cybersecurity protections for their roadside devices, traffic systems, and intelligent transportation solutions and underscores Rekor's dedication to addressing the pressing security concerns of state transportation departments, metropolitan planning organizations, and cities that are increasingly mandating stringent AI and cybersecurity compliance measures.

07:40 EDT Nextech3D.AI closes Map Dynamics sale to ARway.ai - Nextech3D.AI (NEXCF) announces its has closed its previously announced sale of Map Dynamics to ARway.ai as a strategic pivot towards becoming a specialized AI 3D firm. The company has divested its Map Dynamics business, a non-core floor plan mapping software unit, to ARway (ARWYF), in exchange for $1.2 million or 4 million shares in ARway, entirely in stock. This move streamlines Nextech3D.ai's operations, focusing exclusively on its profitable AI-driven 3D modeling patented technology. The divestiture not only advances Nextech3D.ai's position in 3D modeling and AI technology but also enhances ARway's financial standing, contributing approximately $1.2 million in revenue and $500,000 in free cash flow, bolstering its growing spatial mapping operations. This strategic reorganization and focus on core competencies underline Nextech3D.ai's commitment to leading the evolution of digital commerce through advanced 3D modeling technologies.

07:38 EDT T-Mobile to acquire substantially all of U.S. Cellular in $4.4B transaction - T-Mobile (TMUS) and U.S. Cellular (USM) announced that T-Mobile has agreed to acquire substantially all of U.S. Cellular's wireless operations. This includes U.S. Cellular's wireless customers and stores, as well as certain specified spectrum assets. Additionally, UScellular customers will have the ability to fully participate in the Un-carrier's plans. T-Mobile customers will also get access to U.S. Cellular's network in areas that previously had limited coverage. T-Mobile will pay approximately $4.4B for the assets being acquired from U.S. Cellular in the transaction in a combination of cash and up to $2B of debt to be assumed by T-Mobile through an exchange offer to be made to certain U.S. Cellular debtholders prior to closing. To the extent any debtholders do not participate in the exchange, their bonds will continue as obligations of U.S. Cellular and the cash portion of the purchase price will be correspondingly increased. Following the closing of the transaction, U.S. Cellular will retain ownership of its other spectrum as well as its towers, with T-Mobile entering into a long-term arrangement to lease space on at least 2,100 additional towers being retained. T-Mobile does not expect the transaction to impact the company's 2024 guidance or 2024 authorized shareholder return program. T-Mobile expects this transaction will yield approximately $1B in effective total opex and capex annual run rate cost synergies upon integration, with total cost to achieve the integration currently estimated at between $2.2B to $2.6B. The company plans to reinvest a portion of synergies toward enhancing consumer choice, quality and competition in the wireless industry. The transaction, which is subject to the satisfaction of customary closing conditions and receipt of certain regulatory approvals, is expected to close in mid-2025.

07:35 EDT Clene provides update on expanded access program for CNM-Au8 - Clene and its wholly-owned subsidiary Clene Nanomedicine announced several key updates on its National Institutes of Health-funded Accelerating Access to Critical Therapies Expanded Access Program for CNM-Au8 compassionate use in ALS. Late last year, in collaboration with Columbia University and Synapticure, Clene announced the award of a four-year grant from the National Institute of Neurological Disorders and Stroke, part of the NIH, to support an EAP for the Company's investigational drug, CNM-Au8 in ALS. ALS is a deadly neurodegenerative disease with no known cure. In recognizing the need for accessibility and inclusion in such programs for individuals with ALS, Clene instituted significant manufacturing, operational, and personnel efficiencies to expand the program's accommodation to up to 180 participants. In addition to meeting the requisite safety standards set by the FDA for all EAPs, Clene's ACT-EAP was designed to contribute research results to the public understanding of ALS disease progression and response to therapy. To this end, the clinical teams at Clene, Columbia, and Synapticure designed the ACT-EAP for CNM-Au8 with the following additional objectives: To add 'real-world' drug exposure data to the growing clinical safety database on CNM-Au8; To assess 'real-world' drug efficacy data by monitoring potential drug effects on survival and disease progression with the use of natural history and control clinical trial database comparators. Biomarker data will also be collected and analyzed in parallel. First patient, first visit is planned for early June 2024; Enrollment has been expanded by 80% to a maximum of 180 participants; 'Real-world' drug efficacy data will be collected by monitoring potential drug effects on survival and disease progression, as well as safety

07:34 EDT U.S. Cellular, Telephone and Data sell wireless assets to T-Mobile for $4.4B - United States Cellular (USM) and Telephone and Data System (TDS) announced they have entered into a definitive agreement to sell UScellular's wireless operations and select spectrum assets to T-Mobile (TMUS) for a purchase price of $4.4B, including a combination of cash and up to approximately $2B of assumed debt. Under the terms of the agreement, T-Mobile will acquire UScellular's wireless operations and approximately 30% of spectrum assets across several spectrum bands. In addition, T-Mobile will enter into a new master license agreement on more than 2,000 towers. The agreement follows a thorough strategic review process announced in August 2023 and has been unanimously recommended by the independent directors of UScellular and unanimously approved by the boards of directors of both UScellular and TDS, an 83% shareholder of UScellular. In connection with the agreement, T-Mobile will enter into a new long-term MLA on a minimum of 2,015 incremental towers owned by UScellular and extend the lease term for the approximately 600 towers where T-Mobile is already a tenant. This will ensure continued, uninterrupted service for UScellular customers following the transaction and create a long-term contracted revenue stream from a strong anchor tenant for at least 15 years after the close of the transaction. With the inclusion of the towers occupied by other existing third-party tenants, UScellular's tower assets will represent one of the largest and most attractive tower businesses in the United States. The transaction has been unanimously recommended by the independent directors of UScellular and unanimously approved by the boards of directors of both UScellular and TDS. In addition, TDS, in its role as the 83% shareholder of UScellular, has delivered its written consent approving the transaction. No further action by UScellular's shareholders will be needed or solicited in connection with the transaction. The transaction is expected to close in mid-2025, subject to the receipt of regulatory approvals and the satisfaction of customary closing conditions.

07:33 EDT Kanzhun repurchased RMB 74M shares under repurchase plan - KANZHUN recently announced that the Company has implemented a repurchase plan and repurchased nearly 1M ordinary shares with a total value of more than RMB74 million.

07:32 EDT Apogee Therapeutics expands board of directors with appointment of Bollinger - Apogee Therapeutics (APGE) announced that Lisa Bollinger, MD, has been appointed to the company's board of directors. Dr. Bollinger most recently served as Vice President, Regulatory Affairs, Global Regulatory Affairs and Clinical Safety at Merck (MRK), where she led the general medicine therapeutic area in regulatory affairs.

07:31 EDT U.S. Cellular, Telephone and Data sell wireless assets to T-Mobile for $4.4B

07:24 EDT CureVac announces dosing of first participant in Phase 2 study of influenza - CureVac (CVAC) announced dosing of the first participant in a Phase 2 study of the multivalent seasonal influenza vaccine candidate developed in collaboration with GSK (GSK). The study will assess targeted optimizations for improved immune responses of the vaccine candidate against the relevant influenza B strain. This new Phase 2 study in the joint CureVac/GSK seasonal influenza program has been initiated following interim data from the Phase 2 part of the ongoing combined Phase 1/2 study in seasonal influenza reported on April 4, 2024 . The reported data showed that among younger and older adults, serum hemagglutinin inhibition geometric mean titers elicited by the vaccine candidate against influenza A strains numerically exceeded those of the applied licensed comparator vaccines consistently across all tested dose levels. For influenza B strains, serum HAI geometric mean titers were lower than those elicited by the licensed comparator vaccines across tested age groups and dose levels. For the now initiated Phase 2 study, the design of the multivalent vaccine candidate has been changed to address all three World Health Organization-recommended influenza strains, following its recommendation from February 2024 to exclude the influenza B/Yamagata lineage and apply a trivalent vaccine format going forward. The three remaining influenza strains include two influenza A strains and one influenza B strain.

07:19 EDT Aclara extends high grade mineralization thickness at Carina - Aclara Resources provided the drilling results from its Phase 1 reverse circulation drilling campaign executed between November 2023 and April 2024 on its regolith-hosted ion adsorption clay project, known as the "Carina Module", located in the State of Goias, Brazil. The Phase 1 RC drilling campaign, which was comprised of 1,998 meters of drilling within 80 drill holes, has confirmed that the mineralization extends through the full depth of the regolith to the bedrock and provides a greater level of certainty regarding the geological interpretation of the deposit and the existence of rare earth elements throughout the full cross-section of the regolith. Highlights Depth Mineralization Confirmed: Results from the Phase 1 RC drilling campaign confirm that the mineralisation extends through the full depth of the regolith to the bedrock. The average high-grade mineralization thickness has increased from 6.1 meters reported in the previous auger drilling campaign to 11.1 meters. Consistent Grades and Rare Earths Distribution: The results reflect that the Total Rare Earth Oxide 1 and the Desorbible Rare Earth Oxide 2 grades as well as the Rare Earths Distribution in the product basket, are consistent with those reported in the previous auger drilling campaign. Improved Reliability: The results provide a greater understanding of the mineralised horizons through the full depth of the regolith to the bedrock and will support execution of the Phase 2 drilling campaign, which will seek to convert the known inferred mineral resources to a measured and indicated resource category. Metallurgical Compatibility: The Carina Module clays have been shown to be amenable to rare earths extraction using the same metallurgical process developed for the Chile-based Penco Module, which utilizes ammonium sulfate as the primary leaching solution. A 25-tonne bulk sample of Carina clays was processed in the Aclara Pilot Plant in Concepcion, Chile in Q1 2024, where leaching results were consistent with the drill core assays. These results supplement the results obtained from the auger drilling campaign undertaken between February 2023 and September 2023, which comprised 1,630 meters within 201drill holes. The results of the auger drilling campaign also formed the basis of the maiden mineral resource estimate announced in Aclara's press release dated December 12, 2024, and which supported the preparation of the Carina Module Preliminary Economic Assessment dated January 12, 2024.

07:15 EDT Telix Pharmaceuticals submits NDA for new prostate cancer imaging agent - Telix Pharmaceuticals announces it has submitted a New Drug Application, NDA, to the United States Food and Drug Administration, FDA, for TLX007-CDx, a new and proprietary cold kit for the preparation of PSMA-PET imaging for prostate cancer. Subject to regulatory approval, this Kit will enable use of a PSMA imaging product with a considerably extended distribution profile compared to currently approved gallium-68 PSMA-PET imaging agents. The Kit's properties are designed to facilitate more flexible production, including with 68Ga sourced from both newer high activity generators and cyclotrons powered by the ARTMS QUANTM Irradiation System2 and GE FASTlab3 solid and liquid target production system. The Company believes this will further expand the availability, distribution and scheduling flexibility of PSMA-PET imaging.

07:14 EDT Gold Royalty announces agreement to acquire Vares Copper Stream - Gold Royalty announces that it has entered into a binding purchase and sale agreement, PSA, with OMF Fund III Ltd., an entity managed by Orion Mine Finance Management LP to acquire a copper stream on the Vares Silver Project, operated by a subsidiary of Adriatic Metals located in Bosnia and Herzegovina. Under the terms of the PSA, Gold Royalty will pay consideration to Orion of $50M to acquire the Stream at closing of the Transaction, consisting of $45M payable in cash and $5M to be satisfied by the issuance of 2,906,977 Gold Royalty shares.

07:12 EDT Unicycive Therapeutics delivers presentations on OLC, UNI-494 - Unicycive Therapeutics announced that several presentations were delivered on the Company's two product candidates, oxylanthanum carbonate, OLC, and UNI-494, at the 61st European Renal Association, ERA, Congress. Title: Enhanced Urinary Phosphorous Reduction: Comparative Study of Oxylanthanum Carbonate and Tenapanor in Rats. Results: OLC demonstrated a significant reduction in urinary phosphate excretion compared to vehicle treated animals which was 3X greater than the reduction in urinary phosphate excretion observed with tenapanor which was not statistically different from vehicle. OLC and tenapanor utilize two different mechanisms of action to manage phosphate levels. Title: Oxylanthanum Carbonate for Hyperphosphatemia in End Stage Kidney Disease. Results: The primary endpoint of the study is tolerability as assessed by the incidence of discontinuations due to treatment-related AEs; the pharmacokinetics of OLC will also be evaluated. Title: Oral Administration of UNI-494 Ameliorates Acute Kidney Injury in a Rat Model of Delayed Graft Function: Results: The study concluded that UNI-494 is a potential candidate for prevention of DGF and other clinical conditions dealt with AKI. Title: UNI-494 Phase I Tolerability and Pharmacokinetics: Trial in Progress. Results: The SAD study was successfully completed, and a dose of 80 mg twice a day was carried over to the MAD study, which is currently ongoing. Results of this study are expected in the second half of 2024.

07:09 EDT Ocugen set to join Russell 3000 Index - Ocugen announced its expected upcoming inclusion in the Russell 3000 Index, according to preliminary Russell reconstruction information posted on the FTSE Russell website. The newly reconstructed index will take effect after the market closes on June 28, 2024.

07:08 EDT Veradigm initiates process to explore strategic alternatives - Veradigm announced that it has initiated a process to explore strategic alternatives to maximize shareholder value. As part of the evaluation process, Veradigm will explore potential strategic alternatives that may include, but are not limited to, a sale, merger, strategic business combination or other transaction. The company cannot assure that its exploration will result in Veradigm pursuing a transaction or that any transaction, if pursued, will be completed on attractive terms, if at all. Veradigm has not set a timetable for completion of the evaluation process and does not intend to disclose further developments unless and until it is determined that further disclosure is appropriate.

07:06 EDT Opera collaborates with Google Cloud to power its browser AI with Gemini Models - Opera announced a collaboration with Google Cloud to integrate Gemini models into its Aria browser AI. Aria is powered by Opera's multi-LLM Composer AI engine, which allows the Norwegian company to curate the best experiences for its users based on their needs. Opera's Aria browser AI is doesn't just utilize one provider or LLM, its Composer AI engine processes the user's intent and can decide which model to use for which task. Opera also recently opened a green energy-powered AI data cluster in Iceland with NVIDIA DGX supercomputing in order to be able to expand its AI program and host the computing it requires in its own facility. Aria, in Opera One Developer, provides free image generation capabilities by utilizing the Imagen 2 model on Vertex AI.

07:05 EDT Stevanato Group appoints Executive Chairman Franco Stevanato as CEO - Stevanato Group announced that its Board of Directors has appointed Franco Stevanato, a current director and the Executive Chairman of the Company, as its new Chief Executive Officer. Mr. Stevanato is succeeding as Chief Executive Officer Franco Moro, whose employment agreement will continue through June 30, 2024. Mr. Moro will remain on the Company's Board of Directors.

07:04 EDT Actuate files registration statement for initial public offering - Actuate Therapeutics has filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Actuate intends to list its common stock on the Nasdaq Capital Market under the symbol "ACTU". Titan Partners Group, a division of American Capital Partners, is acting as sole book-running manager and Newbridge Securities Corporation is acting as co-manager for the proposed offering.

07:04 EDT Pasithea Therapeutics to present cancer study data showing PAS-004 efficacy - Pasithea Therapeutics announced the publication of data showing that PAS-004, a next-generation macrocyclic MEK inhibitor for the treatment of neurofibromatosis type 1 and other cancer indications, strongly inhibited NRAS mutant cancer cell lines. Maximal growth inhibition of greater than50% was achieved by PAS-004 in more cell lines than binimetinib and selumetinib. In addition, PAS-004's cell line inhibition was comparable to trametinib in 5 cell lines tested but, in contrast to trametinib, PAS-004 did not reach a plateau. The results will be presented at the upcoming ASCO Annual Meeting on June 1. PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials, with an expected extended half-life which may provide better compliance rates, as well as improved efficacy in NF1.

07:03 EDT Siyata Mobile receives order from City of Lancaster for SD7 PTT handsets - Siyata Mobile announced that it has received an order from the City of Lancaster Public Utilities Department for its SD7 Push-to-Talk handsets, VK7 Vehicle Kits and related accessories. The department provides utilities for the residents of Lancaster, Ohio.

07:01 EDT Bausch + Lomb receives Health Canada approval for enVista Envy - Bausch + Lomb announced that Health Canada has approved the enVista Envy full visual range intraocular lens. This is the first global regulatory approval of the new lens, which offers a full range of vision with excellent dysphotopsia tolerance on the widely used enVista IOL platform.

06:59 EDT International Game extends contracts with Mississippi Lottery - International Game announced that its subsidiary, IGT Global Solutions Corporation, has extended its contracts with the Mississippi Lottery for an additional three years to continue providing online gaming systems and instant ticket services through December 1, 2029. As part of the agreements, IGT will deploy a mobile convenience app, new GameTouch 28 self-service terminals and its Sales Wizard retail automation tool.

06:54 EDT Elanco reports FDA confirmation that Bovaer meets safety, efficacy requirements - Elanco announced the FDA has completed its multi-year review of Bovaer, a methane-reducing feed ingredient, and determined the product meets safety and efficacy requirements for use in lactating dairy cattle. "This monumental announcement has the ability to accelerate the opportunity for climate-neutral dairy farming while creating a new revenue stream for dairy farmers across the country," said Jeff Simmons, President and CEO, Elanco Animal Health. "We appreciate FDA's commitment to maintaining high standards for science-based review, while balancing the need to quickly bring solutions to the market. Bovaer represents another example of Elanco being a partner of choice in animal health, where the capabilities of our talented R&D, regulatory and commercial teams are delivering significant value.

06:47 EDT Spire Global to join Russell 3000 Index at open on July 1 - Spire Global is set to join the broad-market Russell 3000 Index, effective at the open of U.S. equity markets on July 1.

06:46 EDT Atlantica Sustainable Infrastructure to be acquired by Energy Capital Partners - Atlantica Sustainable Infrastructure has entered into a definitive agreement pursuant to which a private limited company incorporated in England and Wales has agreed to acquire 100% of the shares of Atlantica for $22 per share in cash. Bidco is controlled by Energy Capital Partners, an investor across energy transition, electrification and decarbonization infrastructure assets, and includes a large group of institutional co-investors. The purchase price represents an 18.9% premium to Atlantica's closing share price on April 22. Further, the purchase price represents a 21.8% premium to the 30-day volume weighted average trading price as of April 22, 2024. The transaction values Atlantica at an equity value of approximately $2.56B. Algonquin Power & Utilities and Liberty, which hold approximately 42.2% of Atlantica's shares, have entered into a support agreement with Bidco pursuant to which Algonquin has agreed, subject to the terms of that agreement, to vote its shares in favor of the Scheme. The transaction is subject to, among other conditions, approval by Atlantica's shareholders of the Scheme, sanction of the transaction by the High Court of Justice of England and Wales, and regulatory approvals in different jurisdictions, including clearance under the HSR Act, by the Committee on Foreign Investment in the U.S. and by the FERC in the U.S. The transaction is expected to close in 4Q24 or early 1Q25. Upon the completion of the transaction, Atlantica will become a privately held company and its shares will no longer be listed on any public market. Atlantica expects to continue paying its current quarterly dividend of $0.445 per share through to the closing of the transaction, subject to the approval of its board of directors.

06:32 EDT Chart Industries supplying hydrogen compression solutions to Repsol in Portugal - Chart Industries (GTLS) has been chosen to supply its Howden hydrogen compression solutions to support Repsol's (REPYY) EUR657M expansion of its Sines industrial complex in Portugal. Repsol's expansion project at its Sines facility is a strategic move towards achieving 100% recyclable high-value materials from two new Polypropylene and Polyethylene plants. This plant will utilize solar-powered green electrolytic hydrogen, aligning with Repsol's commitment to fostering their energy transition initiatives and achieving net-zero emissions by 2050. Chart will supply two diaphragm compressors, ensuring reliable, contamination-free, high-pressure hydrogen delivery for the process. The Alba Project, slated for operation in 2025, will be the largest industrial investment in Portugal in the past decade.

06:29 EDT AstraZeneca says Dato-DXd showed meaningful OS improvement in trial - High-level overall survival, or OS, results from the TROPION-Lung01 Phase III trial, which previously met the dual primary endpoint of progression-free survival, or PFS, numerically favoured datopotamab deruxtecan, or Dato-DXd, compared to docetaxel in the overall trial population of patients with locally advanced or metastatic non-small cell lung cancer, or NSCLC, treated with at least one prior line of therapy, AstraZeneca announced. Survival results did not reach statistical significance in the overall trial population. In the prespecified subgroup of patients with nonsquamous NSCLC, datopotamab deruxtecan showed a clinically meaningful improvement in OS compared to docetaxel, the current standard-of-care chemotherapy. The final analysis of OS builds on the positive progression-free survival results presented at the 2023 European Society for Medical Oncology Congress which showed datopotamab deruxtecan demonstrated a statistically significant improvement in PFS in the overall trial population and a clinically meaningful PFS benefit in patients with nonsquamous NSCLC. In TROPION-Lung01, patient enrolment by tumour histology was balanced across treatment arms and consistent with real-world incidence with approximately 75% of patients having nonsquamous NSCLC. The safety profile of datopotamab deruxtecan in TROPION-Lung01 was consistent with the previous analysis including fewer dose reductions or discontinuations due to adverse events compared to docetaxel, and no new safety concerns identified. No new interstitial lung disease events of any grade were adjudicated as drug-related, the company stated.

06:04 EDT Webuy expanding into insurance referral program - Webuy announced its strategic expansion into an insurance referral program to deliver insurance solutions to markets across Asia. By leveraging its "One on One Match" service, Webuy's insurance referral program pairs each customer with an insurance specialist, who will tailor product recommendations to meet the client's unique needs. The insurance referral program incentivizes Webuy's Group Leaders to promote insurance products and drive referrals within their communities. In turn, Group Leaders earn referral fees based on successful referrals, customers gain access to discounted policies, and insurance partners benefit from lower acquisition costs and higher retention through community engagement.

06:03 EDT Ideaya Biosciences names Daniel Simon chief business officer - Ideaya Biosciences (IDYA) announced that Daniel Simon will join the company as its chief business officer in August. Simon most recently served as chief business officer at Revolution Medicines (RVMD) from 2022 to 2024.

05:35 EDT Trans Global backs cooperation, merger pact with China Hanjiang New Energy - Trans Global Group reaffirmed its global strategic cooperation and partial equity merger and acquisition relationship with China Hanjiang New Energy. The company said, "China Hanjiang New Energy Holdings Co., Ltd., through its wholly-owned subsidiary in China, Shaanxi Ankang Hanjiang New Energy Technology Co., Ltd., is the only company in the southern region of Shaanxi Province that has obtained qualifications for the production, research and development, and sales of methanol fuel. The company's methanol fuel filling station is the first methanol fuel secondary station in the country to be constructed and managed in accordance with "Two Standards." The station is equipped with an automated methanol fuel blending facility with a capacity of 200 cubic meters and an annual production capacity of 100,000 tons. Currently, the company mainly operates methanol fuel products with independent intellectual property rights, including: high-clean car methanol fuel (suitable for gasoline engine vehicles); oxygen-containing clean car methanol fuel (suitable for diesel engine vehicles); M100 car methanol fuel; high-clean civil methanol fuel (for stoves); high calorific value boiler methanol fuel, and clean marine methanol fuel, totaling six main products. Methanol fuel will be an indispensable part of the new energy industry, and there is an expectation for Hanjiang Energy to have a broader market."

05:26 EDT Calliditas Therapeutics board recommends shareholders accept Asahi offer - The board of directors of Calliditas Therapeutics unanimously recommends that the shareholders and holders of American Depositary Shares of Calliditas Therapeutics accept the public tender offer by Asahi Kasei Corporation. This statement is made by the board of Calliditas Therapeutics pursuant to section II.19 of the Nasdaq Stockholm takeover rules and Regulation 14D under the Securities Exchange Act of 1934, as amended. Asahi Kasei announced a public cash offer to acquire all shares in Calliditas for SEK 208 in cash per share. The offer will also include a concurrent offer by the offeror to acquire all American Depositary Shares, each representing two shares in Calliditas, for SEK 416 in cash per ADS, which will be conducted pursuant to the securities rules of the United States. The total value of the offer corresponds to SEK 11.16B. The acceptance period of the offer is expected to commence on or around July 18 and expire on or around August 30, subject to any extensions. Completion of the offer is conditional upon customary conditions including, amongst other things, Asahi Kasei becoming the owner of more than 90 per cent of the shares in Calliditas and receipt of all necessary regulatory, governmental or similar clearances, approvals and decisions, including from competition authorities and agencies screening foreign direct investments, in each case on terms that, in the offeror's opinion, are acceptable. Asahi Kasei has reserved the right to waive, in whole or in part, these and other conditions for completion of the Offer. Asahi Kasei has also reserved the right to shorten the acceptance period and set an earlier settlement date as well as to extend the acceptance period and to postpone the settlement date, as may be permissible under applicable laws and regulations. At the written request of the offeror, the board has permitted the offeror to carry out a due diligence review of Calliditas in relation to the preparation of the offer. In connection with such review, Asahi Kasei has received certain information concerning the company's financial performance for the period up to and ended March 31 as well as a trading update for the period until May 23. This information was subsequently included in the company's quarterly report for the first quarter of 2024, which was released on May 23. Except as set out above, Asahi Kasei has not received any inside information in connection with its due diligence review. BVF Partners, Linc AB and Stiftelsen Industrifonden, the three largest Securityholders of Calliditas together with other large Securityholders, whose combined interest in the company represents approximately 44.65% of the total number of shares, have entered into undertakings with the offeror to accept the offer, subject to certain conditions.